Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PHYTOHEALTH CORPORATION

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

Phase 2

Recruiting

Conditions: Cancer-related Fatigue

Interventions: Drug: PG2 Lyo. Injection 500mg
Drug: Placebo 0.9% normal saline

First Posted Date: 2022-06-30

Last Posted Date: 2025-06-05

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 36

Registration Number: NCT05440227

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Cancer-related Fatigue
Survival
Tumor, Esophageal

Interventions: Drug: Astragalus Polysaccharides 500 mg

First Posted Date: 2018-08-02

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 48

Registration Number: NCT03611712

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
🇨🇳
Far Eastern Memorial Hospital, Taipei, Taiwan

and more 1 locations

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Phase 2

Completed

Conditions: Neutropenia, Malignant
Cancer-related Fatigue

Interventions: Drug: Placebo
Drug: Astragalus polysaccharides 500 mg
Procedure: EC Chemotherapy

First Posted Date: 2017-10-19

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 67

Registration Number: NCT03314805

Locations: 🇨🇳
Chang Gung Memorial Hospital, Lovers Lake branch, Keelung, Taiwan
🇨🇳
E-Da Cancer Hospital, Kaohsiung City, Taiwan
🇨🇳
Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, Taiwan

and more 2 locations

Study of PHN131 in Patients After Surgery

Phase 2

Completed

Conditions: Analgesia Disorder

Interventions: Drug: Placebo soft capsules
Drug: PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
Drug: Dicofenac

First Posted Date: 2014-07-17

Last Posted Date: 2025-06-05

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 106

Registration Number: NCT02193620

Locations: 🇨🇳
General Clinical Research Center, Tri-service General Hospital, Taipei city, Taiwan

Study of PHN131 in Healthy Volunteers

Terminated

Conditions: Analgesia Disorder

First Posted Date: 2014-07-16

Last Posted Date: 2025-06-06

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 16

Registration Number: NCT02192151

Locations: 🇨🇳
General Clinical Research Center, Tri-service General Hospital, Taipei, Taiwan

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

Phase 2

Withdrawn

Conditions: Surgery
Fatigue
Cancer

Interventions: Drug: Placebo
Drug: PG2

First Posted Date: 2014-03-04

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Registration Number: NCT02077621

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

Phase 4

Completed

Conditions: Cancer-related Fatigue

Interventions: Drug: Astragalus Polysaccharides 500 mg
Drug: Astragalus Polysaccharides 250 mg

First Posted Date: 2012-11-02

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 323

Registration Number: NCT01720550

Locations: 🇨🇳
Chang Gung Memorial Hospital, Lovers Lake Branch, Keelung, Taiwan
🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳
Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, Taiwan

and more 6 locations

A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

Phase 2

Terminated

Conditions: Cancer-related Fatigue

Interventions: Drug: Astragalus polysaccharides 500 mg
Drug: Placebo
Procedure: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks

First Posted Date: 2012-11-02

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 17

Registration Number: NCT01720563

Locations: 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Phase 1

Completed

Conditions: Neoplasm Metastasis
Neoplasm Recurrence

Interventions: Drug: PG2

First Posted Date: 2012-10-01

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 32

Registration Number: NCT01696565

Locations: 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan

The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke

Early Phase 1

Completed

Conditions: Hemorrhagic Stroke

Interventions: Drug: PG2
Drug: Placebo

First Posted Date: 2011-03-29

Last Posted Date: 2025-06-04

Lead Sponsor: PhytoHealth Corporation

Target Recruit Count: 61

Registration Number: NCT01325233

Locations: 🇨🇳
China Medical University Hospital, Taichung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy